Fingolimod (FTY720), an FDA ‐approved sphingosine 1‐phosphate (S1P) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection
AbstractExtensive vascular leakage and shock is a major cause of dengue-associated mortality. At present, there are no specific treatments available. Sphingolipid pathway is a key player in the endothelial barrier integrity; and is mediated through the five sphingosine-1-phosphate receptors (S1PR1-S1PR5). Signaling through S1PR2 promotes barrier disruption; and in Dengue virus (DENV)-infection, there is overexpression of this receptor. Fingolimod (FTY720) is a specific agonist that targets the remaining barrier-protective S1P receptors, without targeting S1PR2. In the present study, we explored whether FTY720 treatment can...
Source: IUBMB Life - November 30, 2023 Category: Research Authors: Ayan Modak,
Srishti Rajkumar Mishra,
Mansi Awasthi,
Arya Aravind,
Sneha Singh,
Easwaran Sreekumar Tags: SPECIAL ISSUE Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
